Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:BCYCNASDAQ:CBAYNASDAQ:COLL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.56-1.4%$4.10$3.21▼$8.06$863.71M0.594.53 million shs3.48 million shsBCYCBicycle Therapeutics$7.42+0.1%$8.20$6.10▼$28.67$513.17M1.46390,853 shs346,706 shsCBAYCymaBay Therapeutics$32.48$32.44$7.26▼$32.50$3.73B0.324.11 million shs73 shsCOLLCollegium Pharmaceutical$29.83+0.8%$28.57$23.23▼$42.29$951.10M0.63410,598 shs669,952 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-1.39%-1.11%-10.78%-30.60%-40.17%BCYCBicycle Therapeutics+0.13%-11.35%-7.83%-18.28%-64.24%CBAYCymaBay Therapeutics0.00%0.00%0.00%0.00%0.00%COLLCollegium Pharmaceutical+0.78%+2.23%+1.22%-0.73%-7.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.0674 of 5 stars3.51.00.04.42.72.50.6BCYCBicycle Therapeutics3.3911 of 5 stars4.41.00.00.02.14.20.6CBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACOLLCollegium Pharmaceutical3.8389 of 5 stars3.41.00.03.02.40.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89205.87% UpsideBCYCBicycle Therapeutics 2.70Moderate Buy$25.00236.93% UpsideCBAYCymaBay Therapeutics 0.00N/AN/AN/ACOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7546.66% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, BCYC, CBAY, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/5/2025BCYCBicycle TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.005/2/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.005/2/2025BCYCBicycle TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.005/2/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.005/2/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/1/2025BCYCBicycle TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.004/9/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M2.55N/AN/A$0.73 per share4.88BCYCBicycle Therapeutics$35.28M14.56N/AN/A$11.48 per share0.65CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59COLLCollegium Pharmaceutical$631.45M1.52$12.43 per share2.40$7.10 per share4.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A11.48N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)BCYCBicycle Therapeutics-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)CBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/ACOLLCollegium Pharmaceutical$69.19M$1.2224.454.96N/A6.61%99.08%15.14%8/6/2025 (Estimated)Latest ARDX, BCYC, CBAY, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million5/1/2025Q1 2025BCYCBicycle Therapeutics-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ABCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81BCYCBicycle TherapeuticsN/A14.8614.86CBAYCymaBay TherapeuticsN/A10.9610.96COLLCollegium Pharmaceutical3.301.081.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%BCYCBicycle Therapeutics86.15%CBAYCymaBay Therapeutics95.03%COLLCollegium PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%BCYCBicycle Therapeutics22.90%CBAYCymaBay Therapeutics7.00%COLLCollegium Pharmaceutical2.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableBCYCBicycle Therapeutics24069.25 million53.40 millionOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableARDX, BCYC, CBAY, and COLL HeadlinesRecent News About These CompaniesQ1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals StocksJune 20 at 8:08 AM | msn.comGAMMA Investing LLC Boosts Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 19 at 3:03 AM | marketbeat.comExchange Traded Concepts LLC Decreases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 18 at 3:58 AM | marketbeat.com1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your RadarJune 17, 2025 | msn.comAssenagon Asset Management S.A. Sells 47,897 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 17, 2025 | marketbeat.comJohn G. Freund MD At Collegium Pharmaceutical Decides to Exercises Options Worth $243KJune 12, 2025 | benzinga.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Sells $202,122.62 in StockJune 12, 2025 | insidertrades.comInsider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Sells 6,601 Shares of StockJune 11, 2025 | marketbeat.comCOLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment PrioritiesJune 10, 2025 | msn.comStocks To Watch: Dr. Reddy's Labs ADR Sees Relative Strength Rating Jump To 81June 6, 2025 | msn.comBranded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs PeersJune 6, 2025 | msn.comWellington Management Group LLP Lowers Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 6, 2025 | marketbeat.com1 Stock Under $50 with Exciting Potential and 2 to Turn DownJune 4, 2025 | finance.yahoo.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $3.49 Million in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 2, 2025 | marketbeat.comTwo Sigma Investments LP Sells 135,582 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 2, 2025 | marketbeat.comBank of America Corp DE Reduces Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 2, 2025 | marketbeat.comSquarepoint Ops LLC Decreases Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 145,300 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)May 30, 2025 | marketbeat.comMillennium Management LLC Raises Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)May 30, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Ameriprise Financial Inc.May 30, 2025 | marketbeat.comDeutsche Bank AG Grows Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)May 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, BCYC, CBAY, and COLL Company DescriptionsArdelyx NASDAQ:ARDX$3.56 -0.05 (-1.39%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.59 +0.03 (+0.87%) As of 06/20/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Bicycle Therapeutics NASDAQ:BCYC$7.42 +0.01 (+0.13%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.27 -0.15 (-2.04%) As of 06/20/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.CymaBay Therapeutics NASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Collegium Pharmaceutical NASDAQ:COLL$29.83 +0.23 (+0.78%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$29.81 -0.02 (-0.07%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
